Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis

N Engl J Med. 2020 Jun 25;382(26):2573-2574. doi: 10.1056/NEJMc2000343.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Inhalation
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Drug Combinations
  • Humans
  • Immunotherapy / adverse effects
  • Lung / diagnostic imaging
  • Male
  • Melanoma / drug therapy
  • Phentolamine / administration & dosage*
  • Pneumonia / chemically induced
  • Pneumonia / diagnostic imaging
  • Pneumonia / drug therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Tomography, X-Ray Computed
  • Vasoactive Intestinal Peptide / administration & dosage*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Drug Combinations
  • Programmed Cell Death 1 Receptor
  • Vasoactive Intestinal Peptide
  • aviptadil
  • pembrolizumab
  • Phentolamine